Comparison of the effects of 7.2% hypertonic saline and 20% mannitol on whole blood coagulation and platelet function in dogs with suspected intracranial hypertension - a pilot study. by Yozova, Ivayla et al.
RESEARCH ARTICLE Open Access
Comparison of the effects of 7.2%
hypertonic saline and 20% mannitol on
whole blood coagulation and platelet
function in dogs with suspected
intracranial hypertension - a pilot study
Ivayla D. Yozova1, Judith Howard2, Diana Henke3, Daniel Dirkmann4 and Katja N. Adamik5*
Abstract
Background: Hyperosmolar therapy with either mannitol or hypertonic saline (HTS) is commonly used in the
treatment of intracranial hypertension (ICH). In vitro data indicate that both mannitol and HTS affect coagulation
and platelet function in dogs. The aim of this study was to compare the effects of 20% mannitol and 7.2% HTS on
whole blood coagulation using rotational thromboelastometry (ROTEM®) and platelet function using a platelet
function analyzer (PFA®) in dogs with suspected ICH. Thirty client-owned dogs with suspected ICH needing
osmotherapy were randomized to receive either 20% mannitol (5 ml/kg IV over 15 min) or 7.2% HTS (4 ml/kg IV
over 5 min). ROTEM® (EXTEM® and FIBTEM® assays) and PFA® analyses (collagen/ADP cartridges) were performed
before (T0), as well as 5 (T5), 60 (T60) and 120 (T120) minutes after administration of HTS or mannitol. Data at T5, T60
and T120 were analyzed as a percentage of values at T0 for comparison between groups, and as absolute values for
comparison between time points, respectively.
Results: No significant difference was found between the groups for the percentage change of any parameter at
any time point except for FIBTEM® clotting time. Within each group, no significant difference was found between
time points for any parameter except for FIBTEM® clotting time in the HTS group, and EXTEM® and FIBTEM®
maximum clot firmness in the mannitol group. Median ROTEM® values lay within institutional reference intervals in
both groups at all time points, whereas median PFA® values were above the reference intervals at T5 (both groups)
and T60 (HTS group).
Conclusions: Using currently recommended doses, mannitol and HTS do not differ in their effects on whole blood
coagulation and platelet function in dogs with suspected ICH. Moreover, no relevant impairment of whole blood
coagulation was found following treatment with either solution, whereas a short-lived impairment of platelet
function was found after both solutions.
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Background
Osmotherapy is commonly used in the treatment of
intracranial hypertension (ICH) due to a variety of
causes, including head trauma, intracranial neoplasia, in-
fection or hemorrhage, and status epilepticus [1]. The
principle goal of osmotherapy is to shift fluid from the
intracellular into the extracellular compartment using
intravenous hyperosmolar agents, thereby reducing brain
edema and improving cerebral perfusion pressure [2].
Although 10–20% mannitol is considered the gold
standard hyperosmolar agent in the treatment of ICH
[3], mannitol-induced osmotic diuresis may cause hypo-
volemia and reduction in cerebral perfusion pressure [1].
In recent years, 3.0–7.5% hypertonic saline (HTS) has
gained popularity in the treatment of ICH [4, 5] as it has
less pronounced diuretic effects and therefore does not
cause hypovolemia [1, 6]. Indeed, in the face of hypovol-
emic shock and traumatic brain injury, HTS provides
the advantage of volume expansion, restoring adequate
cerebral perfusion pressures, and reducing brain edema,
which makes it superior to mannitol in trauma patients
with shock [7, 8].
Both mannitol and HTS have been shown to interfere
with whole blood coagulation and platelet function [9].
This is in part due to dilutional coagulopathy. Further-
more, 7.2% HTS may directly disturb both fibrin forma-
tion and platelet function [10], and mannitol may
interfere with coagulation by reducing clot strength [11].
In addition, hyperosmolarity is supposed to lead to im-
pairment of both whole blood coagulation and platelet
function [9, 12]. In consequence, the safety of using these
agents in patients with ICH and intracranial hemorrhage
remains unclear [4, 11, 13]. Previous in vitro studies in
humans have demonstrated anticoagulant effects of both
mannitol and HTS [9, 14], although one clinical study
failed to demonstrate any negative effect on hemostasis
using either solution in patients undergoing elective intra-
cranial surgery [15]. Similarly, in vitro studies in dogs
demonstrated that both mannitol and HTS have negative
effects on coagulation in a dose-dependent fashion, al-
though in vivo studies in dogs in a clinical setting are
lacking [16, 17]. As a result, current guidelines for
osmotherapy in dogs with ICH are largely extrapolated
from experimental data and human literature [18, 19].
The aim of this study was to compare the effects of
clinically recommended doses of 20% mannitol and 7.2%
HTS on whole blood coagulation using rotational
thromboelastometry (ROTEM®) and on platelet function
using a platelet function analyzer (PFA®) in dogs with
suspected ICH. Based on a previous canine in vitro
study, we expected that mannitol would have a greater
impact on coagulation than HTS [17]. A second aim was
to compare plasma osmolarity after either osmothera-
peutic solution. Knowledge of the extent to which these
solutions may impact global hemostasis may influence
clinical decision-making in the selection of solutions for
individual dogs.
Methods
The study was designed as a prospective, randomized,
non-blinded cohort study using client-owned dogs with
suspected ICH. The trial was approved the Animal Experi-
ment Committee of the Swiss Federal Veterinary Office
(registration number BE 90/13), and informed owner con-
sent was obtained for all dogs.
Animals
Dogs with suspected ICH requiring osmotherapy were
enrolled between March 2013 and March 2016. A tenta-
tive diagnosis of ICH was based on history, neurologic
examination (performed by a board-certified neurologist)
and/or magnetic resonance or computed tomographic
imaging studies (evaluated by a board-certified radiolo-
gist or neurologist). Criteria to substantiate suspicion of
ICH were a forebrain or multifocal localization with severely
reduced consciousness and miotic pupils on neurological
exam, Cushing triad (irregular respiration, bradycardia, and
systolic hypertension), brain herniation or other shifts of
brain parenchyma on MRI or CT [20], an elevated resistive
index [21], and deterioration of modified Glasgow coma
scale scores [22]. The decision to administer osmotherapy
was at the clinicians’ discretion. Exclusion criteria were azo-
temia (plasma creatinine concentration > 140 μmol/L), body
weight < 7 kg, age < 6 months or >12 years, presence of dis-
eases known to affect coagulation (hyperadrenocorticism,
protein losing enteropathy or nephropathy, and hepatic
insufficiency) and administration of non-steroidal anti-
inflammatory drugs, osmotherapeutics (mannitol, HTS),
artificial colloids, or blood products within two weeks
prior to study enrollment. In addition, dogs were excluded
if their initial hematocrit was below 0.25 L/L or if platelet
counts were below 100 × 109/L, as this may influence re-
sults PFA assays [23]. Clinical data collected included pa-
tient characteristics (breed, age, gender, and body weight),
the underlying disease causing ICH, and any additional
crystalloid fluid therapy administered within the measure-
ment period.
Treatment groups
Osmotherapeutic solutions used in this study were 20%
mannitol (Dr. G. Bichsel AG, Interlaken, Switzerland)
(osmolarity, 1100 mOsm/L) and 7.2% HTS (Dr. G. Bichsel
AG, Interlaken, Switzerland) (osmolarity, 2464 mOsm/L).
Dogs were randomized to receive either solution by select-
ing a sealed envelope containing a numbered card. Dogs
received either 1 g/kg (5 ml/kg) mannitol administered
over 15 min or 4 ml/kg HTS administered over 5 min
using a syringe pump. Additional crystalloid fluid therapy
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given during the measurement period was at the clini-
cian’s discretion. Animals were excluded if additional
osmotherapy was administered during the study measure-
ment period.
Measurements
Whole blood coagulation was analyzed using ROTEM®
(ROTEM®, TEM Innovations GmbH, Munich, Germany),
according to the manufacturer’s instructions using
methods previously described for canine samples [24].
Two ROTEM® machines were available to enable parallel
measurements of T0 and T5 samples. Clotting activators
used were EXTEM® (re-calcification and tissue factor
activation) for assessment of the extrinsic pathway and
FIBTEM® (tissue factor activation and platelet inhib-
ition with cytochalasin D) for analysis of the extrinsic
pathway and qualitative assessment of fibrinogen status
(star-tem®, ex-tem®, and fib-tem® reagents, TEM Inno-
vations GmbH, Munich, Germany). Data collected were
clotting time (the time from the start of the measure-
ment until the onset of clotting, CT), clot formation
time (the time between the onset of clotting and a clot
firmness of 20 mm amplitude, CFT), alpha angle (angle
between the baseline and a tangent to the clotting
curve through the 2 mm CT, α), and amplitude 10 (clot
firmness in mm at the amplitude time point of 10 min
after CT, A10), and maximum clot firmness (the max-
imum amplitude of the curve measured in millimeters,
MCF). Platelet function was assessed using a PFA-100®
analyzer (PFA-100®; Siemens Healthcare Diagnostics
AG, Zurich, Switzerland), according to the manufac-
turer’s instructions using methods previously described
for canine samples [23] and collagen/ADP cartridges
(Dade PFA Collagen/ADP Test Cartridge, Siemens
Healthcare Diagnostics AG, Zurich, Switzerland). Briefly,
the time until occlusion of the aperture by platelet plug
formation (closure time, CtPFA) was measured. Institu-
tional reference intervals (RI) for ROTEM® and PFA® used
in this study were previously established from jugular
blood samples of 37 healthy dogs. Hematocrits and plate-
let counts were measured using a hematology analyzer
(Advia® 120, Siemens Healthcare Diagnostics AG, Zurich,
Switzerland) and plasma osmolarity was measured using a
freezing-point osmometer (Osmometer Type 1, Loeser
Messtechnik, Germany).
Blood sampling
Blood samples were obtained prior to (T0), and five (T5),
60 (T60), and 120 min (T120) after the end of osmother-
apy administration. At each time point, blood was ob-
tained by careful puncture of the lateral saphenous vein
using a 21G butterfly needle connected to a vacutainer
system. To minimize contamination of the whole blood
samples with tissue factor, the first and third blood
samples were collected from the right saphenous vein
and the second and fourth from the left saphenous vein.
Blood was collected in the following order: one serum
vacutainer tube (discard tube), two 3.2% buffered sodium
citrate vacutainer tubes (BD Vacutainer 1.8 ml coagula-
tion tube, buffered trisodium citrate 3.2%, BD, Plymouth,
United Kingdom) for PFA® and ROTEM® analyses, one
heparin tube (Li-Heparin LH/1.3, 1.3 ml tubes, Sarstedt
AG, Sevelen, Switzerland) for osmolarity and one K2-EDTA
tube (K2-EDTA 2 ml tubes, Sarstedt AG, Sevelen,
Switzerland) for hematocrit and platelet counts. Blood
samples for ROTEM® and PFA® analyses were maintained
at room temperature and analyses were started after
30-60 min. Hematocrits, platelet counts and osmolarity
were measured within 4 h of sampling. All blood sam-
ples were collected and analyzed by the same investiga-
tor (IY).
Statistical analysis
Descriptive statistics were evaluated and continuous var-
iables were assessed for normality using the D’Agostino-
Pearson test and by examining normal plots. Differences
between groups (mannitol vs HTS) were evaluated using
independent samples t-tests and Mann-Whitney tests for
normal and non-normal distributed continuous data, re-
spectively, and chi-squared tests were used for categorical
data. For comparison between the groups for ROTEM®
and PFA® assays, data at T5, T60 and T120 were evaluated
as a percentage of the values measured at T0 in each dog.
Repeated measures analyses within each group for
osmolarity were performed using a Friedman test and
post-hoc pair-wise analysis was applied using Wilcoxon
tests with Bonferroni correction. Repeated measures
analyses within each group for ROTEM® and PFA® mea-
surements were performed using a Skillings-Mack test,
which is a generalization of the Friedman test for incom-
plete blocks when observations are missing arbitrarily.
All data were analyzed using statistical software (MedCalc®
version 16.4.3, MedCalc® Software bvba, Ostend, Belgium
and Statext version 2.7.17, Statext LLC, Wayne NJ, USA)
and significance was set at P < 0.05 throughout.
Results
A total of 30 dogs were included in the study (15 dogs
in each group). Dogs had a mean age of 6.2 ± 3.4 years
and a mean body weight of 25.9 ± 13.6 kg. There were
13 female dogs (5 sexually intact, 8 spayed) and 17 male
dogs (8 sexually intact, 9 castrated). No significant differ-
ence was found between groups for age (P = 0.99), body
weight (P = 0.31), or gender (P = 0.72). Breeds repre-
sented were mixed-breed (n = 4), French bulldog
(n = 4), golden retriever (n = 4), Labrador retriever
(n = 3), border collie (n = 2) and 1 each of boxer, cocker
spaniel, flat coated retriever, fox terrier, German
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shepherd, great Dane, Jack Russel terrier, Keeshond,
Malinois, mudi, Saint Bernard, Tervuren, and white
Swiss shepherd. Of the 30 dogs, 24 underwent magnet
resonance imaging and 1 dog underwent computed
tomography. Underlying diseases were intracranial neo-
plasia (n = 8, mannitol group; n = 8, HTS group), in-
toxication (n = 3, mannitol group; n = 1, HTS group),
head trauma (n = 2, mannitol group; n = 1, HTS group),
meningoencephalitis (n = 2, mannitol group), hydroceph-
alus internus (n = 1, HTS group), presumptive hypertensive
encephalopathy (n = 1, HTS group), and undetermined in
the remaining 3 dogs (HTS group).
In some samples, the anticipated analyses could not be
carried out due to technical constraints (sample clotting
or measurement error). In addition, blood samples of 7
dogs at T60 and a further 3 dogs at T120 could not be ob-
tained due to euthanasia prior to the measurement time
point. The number of samples used for each analysis is
presented in Tables 1 and 2. During the two-hour study
period, 19 of 30 dogs received intravenous isotonic crys-
talloid therapy (median, 5 ml/kg; range, 2–20 ml/kg).
Osmolarity, hematocrit and platelet counts
No significant difference was found in osmolarity,
hematocrit or platelet counts between dogs that received
mannitol and those that received HTS at any time point
(Table 1). Within group comparisons revealed a significant
increase in osmolarity at T5, T60 and T120 after HTS and
at T5 and T60 after mannitol (Table 1).
Platelet function analysis
At T0, CtPFA was significantly longer in the HTS group
than in the mannitol group (P = 0.03) but median values
were within the RI (Table 2). After treatment, median
values were increased above the RI at T5 (both groups)
and T60 (HTS group). However, no significant difference
in percentage relative to values at T0 was found between
the groups at T5, T60, or T120 (Table 3) and no difference
was found between measurement times within either
group (Table 2).
ROTEM® analysis
No significant difference was found for any parameter
between the groups at T0 (Table 2) and no significant
difference between the groups in percentage relative to
T0 was found for any parameter except for a shortening
of FIBTEM® CT at T5 and T60 after HTS (Table 3). No
significant difference was found between measurement
times within either group except for a decrease of
EXTEM® MCF at T5 and FIBTEM® MCF at T5 and
T60compared to T0 in dogs receiving mannitol, and a de-
crease of FIBTEM® CT at T5, T60, and T120 compared to
T0 in dogs receiving HTS (P < 0.05). Median values
where within RI at all time points in both groups.
Discussion
The present study evaluated the effects on coagulation
of intravenous 20% mannitol and 7.2% HTS in a cohort
of dogs with suspected ICH using ROTEM® and PFA®
analyses. Only minimal differences in coagulation parame-
ters were found between dogs treated with mannitol and
those receiving HTS at currently recommended doses. In-
deed, a significant difference between the groups in per-
cent of values relative to baseline (T0) was only found for
FIBTEM® CT, which showed a shorter time until clot de-
tection at T5 and T60 in dogs receiving HTS. This was
mirrored by a shorter FIBTEM® CT at T5, T60, and T120
compared to T0 in the HTS group. Furthermore, a
Table 1 Osmolarity, hematocrit and platelet counts prior to (T0), and at 5 (T5), 60 (T60) and 120 (T120) minutes after administration of
mannitol and hypertonic saline (HTS)
Variable Time point Osmotherapeutic solution and sample size P value
Sample size Mannitol Sample size HTS
Osmolarity
(RI: 300-310 mOsm/L)
T0 15 312 (308–327) 15 311 (309–320) 0.89
T5 15 329 (321–339)* 15 336 (324–340)* 0.96
T60 11 326 (318–341)* 12 324 (317–336)* 0.62
T120 8 327 (316-334) 11 326 (319–334)* 0.59
Hematocrit
(RI: 0.39-0.57 L/L)
T0 15 0.44 (0.35–0.49) 15 0.41 (0.37–0.49) 0.97
T5 15 0.37 (0.31–0.44) 15 0.37 (0.34–0.42) 0.68
T60 11 0.37 (0.35–0.41) 12 0.38 (0.37–0.42) 0.42
T120 8 0.42 (0.35–0.44) 11 0.40 (0.36–0.42) 0.70
Platelet count
(RI: 150-400 × 109/L)
T0 15 221 (167–375) 15 237 (173–312) 0.91
T5 15 202 (157–314) 15 202 (179–287) 0.82
T60 11 207 (169–344) 12 177 (134–284) 0.56
T120 8 214 (188–393) 11 205 (141–269) 0.31
Values are shown as median (interquartile range), RI reference intervals; * values differing significantly from T0 (P < 0.05)
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Table 2 Rotational thromboelastometry and platelet function analysis closure time prior to (T0), and at 5 (T5), 60 (T60) and 120 (T120)
minutes after administration of mannitol and hypertonic saline (HTS)
Variable Time point Osmotherapeutic solution and sample size
Mannitol Sample size HTS Sample size
CtPFA
(RI: 42-90s)
T0 76 (72-86) 15 90 (75-102) 13
T5 96 (79-127) 15 96 (77-138) 13
T60 85 (76-96) 11 98 (70-113) 12
T120 79 (75-83) 8 78 (71-118) 11
EXTEM® CT
(RI: 20-85 s)
T0 42 (37-50) 15 42 (35-54) 15
T5 41 (32-45) 15 38 (35-50) 15
T60 38 (36-49) 11 40 (34-45) 12
T120 43 (29-46) 9 41 (36-49) 11
EXTEM® CFT
(RI: 55-374 s)
T0 84 (59-129) 14 93 (86-111) 15
T5 114 (74-145) 14 115 (102-124) 14
T60 97 (68-105) 10 115 (99-190) 12
T120 98 (77-125) 8 108 (93-147) 11
EXTEM® A10
(RI: 17-69 mm)
T0 58 (46-62) 15 54 (49-61) 15
T5 56 (46-58) 15 51 (39-61) 14
T60 57 (53-67) 11 54 (53-67) 12
T120 60 (52-63) 9 55 (44-56) 11
EXTEM® α-angle
(RI: 57-86°)
T0 73 (61-81) 14 72 (69-75) 15
T5 76 (65-71) 14 67 (64-71) 14
T60 72 (69-79) 10 69 (64-77) 12
T120 69 (65-81) 8 70 (65-75) 11
EXTEM® MCF
(RI: 29-75 mm)
T0 68 (52-69) 15 66 (59-69) 15
T5 65 (51-67)* 15 62 (51-67) 14
T60 67 (64-74) 11 63 (50-67) 12
T120 68 (61-71) 9 63 (58-65) 11
FIBTEM® CT
(RI: 18-72 s)
T0 38 (31-44) 15 42 (36-46) 14
T5 36 (32-44) 15 33 (32-39)* 14
T60 39 (33-50) 11 35 (30-36)* 11
T120 40 (32-44) 9 35 (36-42)* 10
FIBTEM® A10
(RI: 2-17 mm)
T0 12 (10-21) 15 11 (6-15) 14
T5 11 (10-17) 15 10 (7-13) 14
T60 14 (10-21) 11 10 (9-15) 11
T120 16 (11-17) 9 11 (8-15) 10
FIBTEM® α-angle
(RI: 61-88°)
T0 75 (65-79) 13 67 (65-74) 10
T5 75 (67-81) 11 72 (70-75) 10
T60 77 (74-79) 8 67 (62-76) 8
T120 76 (64-78) 8 72 (61-77) 6
FIBTEM® MCF
(RI: 3-17 mm)
T0 14 (9-20) 15 12 (7-16) 14
T5 13 (9-19)* 15 11 (8-13) 13
T60 14 (9-18)* 11 10 (9-15) 11
T120 15 (13-18) 9 12 (9-15) 10
CtPFA platelet closure time, CT clotting time, CFT clot formation time, A10 clot firmness amplitude 10 min after CT, MCF maximal clot firmness; variables are shown
as median (interquartile range), RI institutional reference intervals; bold font, median value outside of the RI; *, significant different to T0 (P < 0.05)
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short-lived decrease in EXTEM® and FIBTEM® MCF
was observed after mannitol. However, median
ROTEM® values remained within institutional RIs at all
time points in both groups. In contrast, PFA® values in-
creased above institutional RIs after mannitol (T5) and
HTS (T5 and T60), although no significant differences
were found between groups or time points. In terms of
the importance of the detected changes, alterations in
FIBTEM® CT are most likely of no relevance, as in hu-
man medicine only the clot firmness variables (A5,
A10, etc., and MCF) of the FIBTEM® assay are used
(eg., for deciding on the replacement of fibrinogen
sources) [25]. The very mild changes in MCF and CtPFA
may be signs for a mannitol induced, short-lived fibrin
polymerization defect (decrease in MCF FIBTEM®) as
well as short lived platelet-fibrin interaction defect,
such as impairment of GPIIb/IIIa receptor mediated
binding (decrease in MCF EXTEM® combined with im-
paired platelet function) which might become more
prominent after higher doses. Furthermore, plasma
osmolarity was significantly increased by 15–25 mOsm/
L for up to 1 h (mannitol group) and up to 2 h (HTS
group), respectively, but no difference between the
groups was detected.
Table 3 Rotational thromboelastometry and platelet function analysis closure time (CtPFA) prior to (T0), and at 5 (T5), 60 (T60) and
120 (T120) minutes after administration of mannitol and hypertonic saline (HTS) shown as the percentage of values relative to T0
Osmotherapeutic solution
Variable Time point Mannitol (% from baseline) HTS (% from baseline) P value
CtPFA T5 130 (103-171) 116 (89-151) 0.31
T60 109 (95-126) 112 (89-149) 1.00
T120 100 (93-109) 91 (87-107) 0.32
EXTEM® CT T5 92 (51-113) 91 (60-239) 0.35
T60 107 (70-128) 95 (60-1299 0.21
T120 113 (40-159) 98 (48-143) 0.65
EXTEM® CFT T5 115 (73-246) 118 (84-216) 0.98
T60 111 (62-194) 113 (83-359) 0.97
T120 115 (80-182) 109 (70-162) 0.62
EXTEM® A10 T5 97 (61-122) 98 (16-112) 0.44
T60 103 (86-2014) 102 (88-260) 0.68
T120 97 (92-127) 100 (84-215) 0.37
EXTEM® α-angle T5 98 (65-273) 96 (20-104) 0.48
T60 99 (71-119) 98 (71-109) 0.97
T120 100 (71-113) 100 (93-111) 0.87
EXTEM® MCF T5 97 (70-300) 97 (28-104) 0.86
T60 100 (91-469) 98 (46-106) 0.12
T120 101 (90-446) 97 (89-111) 0.22
FIBTEM® CT T5 100 (70-138) 86 (56-108) 0.01
T60 111 (72-163) 81 (55-110) 0.01
T120 94 (75-142) 85 (25-126) 0.11
FIBTEM® A10 T5 85 (62-167) 103 (15-167) 0.05
T60 114 (82-146) 100 (33-300) 0.76
T120 106 (81-135) 100 (64-200) 0.76
FIBTEM® α-angle T5 101 (80-109) 106 (97-119) 0.09
T60 99 (92-107) 101 (22 (124) 0.60
T120 100 (93-104) 96 (83-112) 0.56
FIBTEM® MCF T5 89 (58-188) 100 (19-171) 0.11
T60 88 (59-104) 100 (14-143) 0.07
T120 88 (62-188) 104 (19-143) 0.60
CtPFA platelet closure time, CT clotting time, CFT clot formation time, A10 amplitude after 10 min, MCF maximal clot firmness; values shown as median
(interquartile range) percentage of measurements relative to T0; bold font, P <0.05
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Previous in vitro studies in humans and dogs indicate
that both mannitol and HTS affect primary and second-
ary hemostasis in a dose-dependent fashion by delayed
clot formation and impairment of fibrin clot firmness
[12, 14, 16, 17]. Indeed, a 1:22 dilution of whole blood
with 7.2% HTS (mimicking a dose of 4 ml/kg) signifi-
cantly affected CtPFA and ROTEM® EXTEM® CFT and
MCF in dogs [16]. Moreover, 20% mannitol affected
CtPFA and ROTEM® EXTEM® variables to a greater ex-
tent than equimolar 3% HTS in dilutions mimicking rec-
ommended clinical doses [17]. However, given the in
vitro nature of these studies and absence of the endothe-
lium and compensatory mechanisms, such as buffering,
electrolyte homeostasis, and metabolic degradation and
excretion of the drug, results may not reflect in vivo
conditions [26]. Moreover, in vitro dilution of blood may
result in a more significant dilution of coagulation fac-
tors than the corresponding in vivo dose, impacting the
kinetics of clot formation. Finally, effects of transen-
dothelial fluid shifts, which are a crucial effect of
osmotherapy, are essentially eliminated by in vitro
studies.
The findings of the present study only partially con-
firm recent in vitro findings [17]. The less pronounced
effect of mannitol in the present study may to some ex-
tent be due to disparate osmolarities of the HTS solu-
tions evaluated (3% HTS in the previous in vitro study
compared to 7.2% in the present study). Indeed, hyper-
osmotic stress may result in impaired enzymatic func-
tion in the clotting cascade, slower clot formation and a
weaker clot [9, 10, 12]. In the present study no signifi-
cant difference in plasma osmolarity was found between
the two groups despite the higher osmolarity and more
rapid administration of HTS. Likewise, no significant dif-
ference in plasma osmolarity was found between 7.2%
NaCl/HES 200/0.5 and 15% mannitol in a previous study
in 40 adult neurosurgical patients [27]. This may, in part,
explain the lack of difference in ROTEM® and PFA® pa-
rameters between the two osmotherapeutic groups.
However, the extent to which the changes observed in
ROTEM® and PFA® parameters were due to increased
osmolarity, increased sodium load, or to additional
hemostatic disturbances from each hyperosmolar mol-
ecule itself remains unclear. Lastly, the volume adminis-
tered in the present study was lower than dilutions used
in some previous in vitro studies, which may have
masked potential coagulation impairing effects at higher
doses.
Similar to the current findings, in two recent studies
in people undergoing elective craniotomy or suffering
from traumatic brain injury, respectively, no difference
in standard coagulation tests and ROTEM® analysis was
found between patients administered 20% mannitol and
those receiving 3% HTS [15, 28].
To the authors’ knowledge, the present study is the
first investigation evaluating platelet function with PFA®
after intravenous administration of mannitol or HTS in
dogs. Despite the 30% increase in CtPFA after mannitol
at T5 and some PFA values above the RI in both groups,
the changes did not reach statistical significance and
returned to normal within the two-hour study period. A
clear advantage of one of the osmotherapeutics to avert
platelet dysfunction was therefore not evident, although
mannitol may have more pronounced but shorter lived
effects compared to HTS.
In contrast to the aforementioned in vitro studies [16, 17],
dogs in the present study were not healthy as they all were
affected by conditions causing suspected ICH. Of the in-
cluded dogs, 53% had intracranial neoplasia, albeit equally
distributed between both treatment groups. Furthermore, 5
dogs (n = 3, HTS group; n = 2, mannitol group) in-
cluded in the study had received one dose of glucocor-
ticoids (≤1 mg/kg) within 7 days prior to the study,
which may be expected to increase clot strength and
decrease clot lysis in thromboelastography [29]. How-
ever, effects on thromboelastographic amplitude and
clot lysis in the respective study were found after two 2
and 4 days of treatment, respectively, with an immuno-
suppressive dose of prednisone (median dose 2.07 mg/kg
per 24 h). In contrast, the dogs in the present study re-
ceived prednisolone in a lower dose and only once. Never-
theless, given heterogeneous diseases and previous
treatments, some dogs included in this study were ex-
pected to have some abnormal initial PFA® or ROTEM®
measurements. Indeed, MCF values were above the RI in
EXTEM® (n = 1) and FIBTEM® (n = 5). This confounder
was cancelled out in the evaluation of differences between
time points by using the percentage of parameters relative
to those measured at T0 instead of absolute values, allow-
ing evaluation of a cohort that truly represents the target
population of dogs receiving osmotherapy. Given the
small numbers of dogs affected by different diseases, no
analyses of associations between disease and coagulation
parameters was performed and further studies are needed
to establish whether certain conditions leading the ICH
are associated with coagulation abnormalities in dogs.
The current guidelines for viscoelastic coagulation
testing recommend blood sampling for ROTEM® by
atraumatic puncture of the jugular vein [30]. However,
as compression of the jugular vein is not recommended
in dogs with ICH, samples were taken from the lateral
saphenous veins in the present study [18]. The extent to
which this may have affected results is not clear.
Artefactual hypercoagulability using ROTEM® analysis
has been shown to occur due to low red blood cell mass
[31, 32]. Likewise, low hematocrits and low platelet
count was found to prolong PFA® results [23]. In the
present study, some dogs were slightly anemic following
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administration of osmotherapeutics but hematocrits did
not fall below 0.30 L/L and platelet counts not fall below
100 × 109/L in any dog at any time point, which is
within the current recommendations for accurate PFA®
testing [23].
The current study has potential limitations. Firstly,
simultaneous standard coagulation testing (prothrombin
time (PT), partial thromboplastin time (aPTT), and fi-
brinogen concentration) was not assessed. Although
ROTEM® analysis enables dynamic assessment of whole
blood coagulation and platelet function, standard coagu-
lation testing may have helped in the interpretation of
the clinical relevance of findings. However, both PT and
aPTT are essentially limited to answering the question
whether any intervention exerts effects on thrombin
generation, depending on the coagulation factors reflected
in the respective assay. As we were not expecting the in-
terventions in our study to exert impacts on thrombin
generation, the information obtainable by additional PT
and aPTT assays would be limited to detect potential ef-
fects induced by dilution. Furthermore, both poor and
good associations between standard coagulation tests and
ROTEM® analyses have been reported [33, 34], and infor-
mation about platelet function, fibrin polymerization, and
platelet interaction with fibrin is not provided by plas-
matic coagulation tests. Further, although there are no re-
sults of any conventional fibrinogen assay available,
variables of clot firmness (MCF and A10) of ROTEM®
FIBTEM® assays are highly correlated with the fibrinogen
concentration [31] and adequately provide information
about potential fibrin-polymerization defects that are not
detectable using standard lab tests. Even if potentially ele-
vated fibrinogen concentrations in some of the dogs might
have alleviated coagulation impairment, importantly no
relevant alteration of fibrin polymerization was found after
osmotherapy in the present study.
Another limitation was that some dogs received add-
itional crystalloid fluid therapy during the study period
as treatment was largely at the discretion of the clini-
cians. Previous in vitro studies in dogs demonstrated a
dilutional coagulopathy caused by 0.9% saline on visco-
elastic coagulation and PFA® testing [16, 35]. Contrariwise,
a recent in vivo study in healthy anesthetized dogs admin-
istered with a 15 ml/kg-bolus of isotonic buffered crystal-
loids did not led to relevant ROTEM® and PFA®
abnormalities [36]. Nevertheless, simultaneous crystalloid
fluid therapy might have impacted results in individual
dogs in the present study. Lastly, although the previous in
vitro study evaluated a 3% HTS solution, dogs in the
present study were given a 7.2% HTS solution as this was
the established institutional treatment protocol for dogs
with ICH. It is likely that more significant differences be-
tween groups would have been found had mannitol been
compared with 3% HTS instead of 7.2% HTS.
Conclusion
In conclusion, results of this pilot study suggest that
mannitol and HTS do not differ in their effects on coagu-
lation when administered in the currently recommended
doses in dogs with suspected ICH. Moreover, no clinically
relevant impairment of whole blood coagulation was
found following treatment with either solution, whereas a
short-lived impairment of platelet function was found
after both solutions. Further studies are warranted before
recommendations can be made with regards to treatment
of individual animals.
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